share_log

EF Hutton Initiates Coverage On Atara Biotherapeutics With Buy Rating, Announces Price Target of $25

EF Hutton Initiates Coverage On Atara Biotherapeutics With Buy Rating, Announces Price Target of $25

EF Hutton以買入評級啟動對Atara生物療法的報道,宣佈目標價為25美元
Benzinga Real-time News ·  2023/01/05 04:45

EF Hutton analyst Tony Butler initiates coverage on Atara Biotherapeutics (NASDAQ:ATRA) with a Buy rating and announces Price Target of $25.

EF Hutton分析師Tony·巴特勒對雅達拉生物療法公司(納斯達克:ATRA)的報道給予買入評級,並宣佈目標價為25美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論